SCHEMBL3594726

SCHEMBL3594726

O=C(O)NCC1CCN(CCc2cc(-c3ccc(Cl)cc3)on2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.46
NOTUM Q6P988 1/20 0.45
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
DRD4 P21917 3/20 0.44
DRD3 P35462 3/20 0.44
DRD2 P14416 2/20 0.44
CYP1A2 P05177 4/20 0.44
CYP2D6 P10635 3/20 0.44
MAPT P10636 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
USP30 Q70CQ3 1/20 0.42
HPGD P15428 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CACNA1I Q9P0X4 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605744 0.94 HIF1A (0.44) HIF1ANOTUMNPC1RAB9ADRD4
SCHEMBL3593611 0.83 USP30 (0.50) NOTUMDRD4DRD3DRD2CYP1A2
SCHEMBL3594728 0.80 NOTUM (0.45) NOTUMNPC1RAB9ADRD4DRD3
SCHEMBL5482230 0.79 NOTUM (0.52) NOTUMNPC1RAB9ACYP1A2CYP2D6
SCHEMBL3594357 0.79 USP30 (0.49) NOTUMDRD4DRD3DRD2POLB
SCHEMBL2965450 0.79 NPC1 (0.39) NOTUMNPC1RAB9ADRD4DRD3
SCHEMBL5709515 0.78 CYP1A2 (0.45) NOTUMNPC1RAB9ADRD4DRD3
SCHEMBL2841498 0.78 NOTUM (0.58) NOTUMNPC1RAB9ACYP1A2CYP2D6
SCHEMBL3593973 0.77 ARG1 (0.51) L3MBTL1CACNA1I
SCHEMBL2965446 0.77 MAPT (0.42) NOTUMNPC1RAB9ADRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP claimed
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 HIF1A 2195/4885NOTUM 47/4885NPC1 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.